Patents by Inventor Ziping Sun

Ziping Sun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Targeted radiotherapy
    Patent number: 8741262
    Abstract: The present invention concerns a therapeutically labeled napthodianthrone or phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound, which comprises a chemical element or an isotope that has an unstable nucleus and emits radiation during its decay to a stable form sufficient to destroy neighboring cells or tissues for use in a targeted radiotherapy to enhance curability of a warm-blooded animal that has been subjected to a necrosis-inducing antitumor therapy. A particular advantage of present invention is that viable rim resistant to a necrosis-inducing antitumor therapy such as vascular targeting agent (VTA) can be supplemented by one single or repeated doses of a therapeutically radiolabeled small molecule necrosis-avid chemical compound treatment to enhance the curability.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: June 3, 2014
    Assignee: Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Yicheng Ni, Marie Van De Putte, Peter DeWitte, Alfons Verbruggen, Guy Marchal, Ziping Sun
  • TARGETED RADIOTHERAPY
    Publication number: 20110038795
    Abstract: The present invention concerns a therapeutically labeled napthodianthrone or phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound, which comprises a chemical element or an isotope that has an unstable nucleus and emits radiation during its decay to a stable form sufficient to destroy neighboring cells or tissues for use in a targeted radiotherapy to enhance curability of a warm-blooded animal that has been subjected to a necrosis-inducing antitumor therapy. A particular advantage of present invention is that viable rim resistant to a necrosis-inducing antitumor therapy such as vascular targeting agent (VTA) can be supplemented by one single or repeated doses of a therapeutically radiolabeled small molecule necrosis-avid chemical compound treatment to enhance the curability.
    Type: Application
    Filed: November 26, 2008
    Publication date: February 17, 2011
    Applicant: KATHOLIEKE UNIVERSITEIT LEUVEN K.U.LEUVEN R&D
    Inventors: Yicheng Ni, Marie Van De Putte, Peter De Witte, Alfons Verbruggen, Guy Marchal, Ziping Sun